MedPath

Diverticulitis: Antibiotics or Close Observation?

Phase 4
Conditions
Diverticulitis
Interventions
Drug: Amoxicillin-clavulanate
Registration Number
NCT01111253
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

Rationale

The prevalence of colonic diverticular disease is increasing in Western countries. Approximately 10 to 25% of patients with diverticular disease will eventually develop an episode of acute diverticulitis. Currently conservative treatment often includes antibiotic therapy. This advice lacks sound evidence and is merely based on experts' opinion. An old clinical dogma is being clarified with this randomized trial.

Objective

Primary objective is to evaluate whether or not using antibiotics reduces to time to full recovery of an attack of uncomplicated (mild) diverticulitis. Secondary objectives are to evaluate complications, quality of life, readmission rate, recurrence rate, medical and non-medical costs, and antibiotic resistance/sensitivity in both groups.

Hypothesis

The investigators hypothesis is that in the treatment of uncomplicated (mild) acute diverticulitis, supportive treatment without antibiotics is a more cost-effective approach than conservative treatment with antibiotics with respect to time-to-recovery as primary outcome.

Study design

A randomized, open label, multicenter clinical trial comparing treatment of acute uncomplicated diverticulitis with antibiotics to observation and supportive care alone.

Study population

Patients 18 years or older are eligible for inclusion if they have a diagnosis of acute uncomplicated diverticulitis as demonstrated by imaging. Only patients with stages 1a and 1b according to Hinchey's classification or "mild" diverticulitis according to the Ambrosetti criteria are included.

Intervention

Conservative strategy with antibiotics: supportive measures and at least 48 hours of intravenous antibiotics (and therefore admittance to the hospital) and subsequently switch to oral antibiotics if tolerated (total duration of 10 days).

Control

Liberal strategy without antibiotics: supportive measures only. Observation and oral intake as tolerated. Admittance only if discharge criteria are not met on presentation.

Main study parameters/endpoints

The primary endpoint is time-to-recovery with a 6-month follow-up period. Secondary endpoints are occurrence of complicated diverticulitis requiring surgery or percutaneous treatment, morbidity, health related quality of life, readmission rate, recurrence rate, medical and non-medical costs, and antibiotic resistance/sensitivity.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
533
Inclusion Criteria
  • Only left-sided uncomplicated (mild) acute diverticulitis;
  • Clinical suspicion of acute diverticulitis. For acute diagnostic work-up: ultrasound or CT proven diverticulitis. In the case of diverticulitis-negative ultrasound in clinically suspected patients an intravenous contrast-enhanced CT scan is mandatory for confirmation of diverticulitis or exclusion of other pathology. CT for Hinchey/Ambrosetti classification (which is a CT-based classification system) is needed for all patients, but can be delayed 1 day in those with ultrasound diagnosis. Staging diverticulitis is defined according the modified Hinchey/Ambrosetti staging, only stages 1a and 1b and "mild" diverticulitis (1a Confined pericolic inflammation, 1b Confined small (smaller than 5cm) pericolic abscess) are included;
  • All patients with informed consent.
Exclusion Criteria
  • Previous radiological (ultrasound and/or CT) proven episode of diverticulitis;
  • Colonic cancer;
  • Inflammatory bowel disease (ulcerative colitis, Crohn's disease);
  • Hinchey stages 2, 3 and 4 or "severe" diverticulitis according to the Ambrosetti criteria, which require surgical or percutaneous treatment;
  • Disease with expected survival of less than 6 months;
  • Contraindication for the use of the study medication (e.g. patients with advanced renal failure or allergy to antibiotics used in this study);
  • Pregnancy, breastfeeding;
  • ASA (American Society of Anaesthesiologists) classification > III;
  • Immunocompromised patients;
  • Clinical suspicion of bacteraemia (i.e. sepsis);
  • The inability of reading/understanding and filling in the questionnaires;
  • Antibiotic use in the 4 weeks before admittance.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conservative strategy with antibioticsAmoxicillin-clavulanate* Hospital admission * Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration * Adequate pain relief * Oral intake as tolerated * Daily monitoring
Primary Outcome Measures
NameTimeMethod
Time-to-full-recovery6 months follow-up
Secondary Outcome Measures
NameTimeMethod
Direct medical costs6 months follow-up
Occurrence of complicated diverticulitis defined as abscess, perforation, stricture and/or fistula and need for percutaneous drainage and/or operation24 months follow-up
Predefined side-effects of initial antibiotic treatment24 months follow-up

e.g. antibiotic resistance/sensitivity pattern, allergy

Morbidity, like urinary tract infection, pneumonia, etc24 months follow-up
Mortality24 months follow-up
Readmission rate6 months follow-up
Indirect medical costs6 months follow-up
Acute diverticulitis recurrence rate24 months follow-up
Health status24 months follow-up

Changes and valuation over time (compared to t=0, 3, 6 and 12 months) will be measured using generic and disease specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the Gastro-intestinal Quality of Life Index (Giqli))

Trial Locations

Locations (23)

Westfries Gasthuis

๐Ÿ‡ณ๐Ÿ‡ฑ

Hoorn, Netherlands

Tergooi Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Hilversum, Netherlands

Kennemer Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Haarlem, Netherlands

Mรกxima Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Veldhoven, Netherlands

Albert Schweitzer Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Dordrecht, Netherlands

Spaarne Hospitals

๐Ÿ‡ณ๐Ÿ‡ฑ

Hoofddorp, Netherlands

Sint Antonius Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Nieuwegein, Netherlands

Erasmus Medical Center

๐Ÿ‡ณ๐Ÿ‡ฑ

Rotterdam, Netherlands

Ikazia Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Rotterdam, Netherlands

Sint Franciscus Gasthuis

๐Ÿ‡ณ๐Ÿ‡ฑ

Rotterdam, Netherlands

Ziekenhuisgroep Twente

๐Ÿ‡ณ๐Ÿ‡ฑ

Hengelo, Netherlands

Flevo Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Almere, Netherlands

Academic Medical Center

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

Meander Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Amersfoort, Netherlands

BovenIJ Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

Onze Lieve Vrouwe Gasthuis

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

Sint Lucas Andreas Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

Slotervaart Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

VU Medical Center

๐Ÿ‡ณ๐Ÿ‡ฑ

Amsterdam, Netherlands

Rijnstate Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Arnhem, Netherlands

Rode Kruis Hospital

๐Ÿ‡ณ๐Ÿ‡ฑ

Beverwijk, Netherlands

Gelre Hospitals

๐Ÿ‡ณ๐Ÿ‡ฑ

Apeldoorn, Netherlands

Reinier de Graaf Gasthuis

๐Ÿ‡ณ๐Ÿ‡ฑ

Delft, Netherlands

ยฉ Copyright 2025. All Rights Reserved by MedPath